Propranolol, a beta-adrenergic receptor (b-AR) antagonist, has shown efficacy in human angiosarcoma, a tumor with similar clinical and morphological characteristics, when combined with chemotherapy. This evidence concerns the gene ADRB2 and neoplasm.